Abstract
Primary care providers are often neglectful of lifestyle interventions in the management of the progression of glucose intolerance to type 2 diabetes. Several studies have examined the benefits of pharmacologic therapy in conjunction with lifestyle modification to delay or retard this progression. This article focuses on 3 of these studies: the DREAM trial, the ADOPT trial, and the Finnish Diabetes Study. All reinforce the use and effectiveness of thiazolidinediones in the prevention of progression, yet active lifestyle intervention complements and maintains a lower diabetes risk over time.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
